<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03758222</url>
  </required_header>
  <id_info>
    <org_study_id>PN 07585</org_study_id>
    <nct_id>NCT03758222</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of the Mercury Expander System</brief_title>
  <acronym>EXPANDER-1</acronym>
  <official_title>A First-In-Human Study to Evaluate the Safety and Feasibility of the Mercury Expander System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedeonBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedeonBio, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the safety and feasibility of the Mercury Expander system and procedure to
      treat patients with lower urinary tract symptoms (LUTS) secondary to urinary outflow
      obstruction from benign prostatic hyperplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, non-randomized, two-arm, multi-center clinical trial designed to evaluate the
      safety and feasibility of the Mercury Expander system in patients with lower urinary tract
      symptoms (LUTS) secondary to urinary outflow obstruction from benign prostatic hyperplasia
      (BPH).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from Unanticipated adverse device effects (UADEs)</measure>
    <time_frame>1 month (Arm-1)</time_frame>
    <description>Measure any device or procedure related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from Unanticipated adverse device effects (UADEs)</measure>
    <time_frame>6 months (Arm-2)</time_frame>
    <description>Measure any device or procedure related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from Unanticipated adverse device effects (UADEs)</measure>
    <time_frame>7 months (Arm-1)</time_frame>
    <description>Measure any device or procedure related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Unanticipated adverse device effects (UADEs)</measure>
    <time_frame>12 months (Arm-2)</time_frame>
    <description>Measure any device or procedure related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Prostate Symptom Score (IPSS)</measure>
    <time_frame>1 month and 7 months (Arm-1)</time_frame>
    <description>Measure improvement in lower urinary tract symptoms related to benign prostatic hyperplasia (BPH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in International Prostate Symptom Score (IPSS)</measure>
    <time_frame>6 and 12 months (Arm-2)</time_frame>
    <description>Measure improvement in lower urinary tract symptoms related to benign prostatic hyperplasia (BPH)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Arm-1: Device implantation for 1 month</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group receives intervention with the Mercury Expander System implantation for 1 month, and then retrieved.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm-2: Device implantation for 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group receives intervention with the Mercury Expander System implantation for 6 months, and then retrieved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mercury Expander System</intervention_name>
    <description>Implantation and retrieval of the Mercury Expander System in the prostatic urethra to treat benign prostatic hyperplasia (BPH)</description>
    <arm_group_label>Arm-1: Device implantation for 1 month</arm_group_label>
    <arm_group_label>Arm-2: Device implantation for 6 months</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male gender

          -  Age ≥ 50 years

          -  Prostate volume 25 - 80 cc by Abdominal Ultrasound (AUS) or Trans Rectal Ultrasound
             (TRUS)

          -  Prostatic urethra length of 3.5-6.0 cm, as measured from bladder neck to verumontanum,
             using cystoscopy (or prostate length from bladder neck to external sphincter of
             4.0-8.0 cm during screening visit, using ultrasound).

          -  Medication history

               -  Not on BPH related medication for the past 6 months.

               -  If on BPH related medication:

                    -  On 5-alpha-reductase inhibitors (ARIs), the patient must be on the
                       medication for at least 3 months with a stable voiding pattern

                    -  On alpha-blockers, the patient must be on the medication for at least 3
                       weeks with a stable voiding pattern

          -  Patients with symptomatic BPH and related lower urinary tract symptoms (LUTS):

               -  With International Prostate Symptom Score (IPSS) &gt; 13; Qmax &lt; 12 mL/sec on a
                  voided volume ≥125 mL; Post-void residual (PVR) &lt; 250 mL; QoL score ≥ 3

               -  Need temporary relief for ≥ 1 month

        Exclusion Criteria:

          -  Previous BPH procedure

          -  Median prostatic lobe or high bladder neck

          -  Urethral stricture, meatal stenosis, or bladder neck obstruction - either current, or
             recurrent requiring 2 or more dilatations

          -  Elevated Prostate Specific Antigen (PSA) ≥ 10 ng/mL unless negative biopsy within last
             6 months, or a positive biopsy showing cancer

          -  Cystolithiasis within the prior 3 months

          -  History of neurogenic bladder or urinary retention with PVR &gt;1000mL.

          -  Serum creatinine &gt;1.8 mg/dl or upper-tract disease which compromises renal function

          -  Current or recent Urinary Tract Infection (UTI) or disease

          -  Known allergy to nickel

          -  Life expectancy of less than 24 months

          -  Known coagulopathies or subject on anticoagulants or antiplatelets other than aspirin
             ≤ 100 mg (unless antiplatelets are withheld minimum 3 days prior to procedure)

          -  Anticipated need for additional surgery or treatments for comorbidities during the
             study period.

          -  Current gross hematuria

          -  Other co-morbidities that could impact the study results

          -  Unable or unwilling to complete all required questionnaires and follow-up assessments

          -  Unable or unwilling to sign informed consent form

          -  Currently enrolled in any other investigational clinical research trial that has not
             completed the primary endpoint.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Benign prostatic hyperplasia (BPH) is a male disease</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Woo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Australian Clinical Trials Pty Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>K. T. Venkateswara Rao, PhD</last_name>
    <phone>650-397-5100</phone>
    <email>kt@medeonbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Australian Clinical Trials Pty Ltd</name>
      <address>
        <city>Wahroonga</city>
        <state>New South Wales</state>
        <zip>2076</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Woo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Henry Woo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center of Urology</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi-Ping Huang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Georgia</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 26, 2018</study_first_submitted>
  <study_first_submitted_qc>November 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2018</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

